Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.

Recent News

C4-logo-400
10/14/2020

C4 Therapeutics to Present at the 3rd Annual Targeted Protein Degradation Summit

READ MORE
C4-logo-400
10/06/2020

C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

READ MORE
C4-logo-400
10/01/2020

C4 Therapeutics Announces Pricing of an Upsized Initial Public Offering

READ MORE
C4-logo-400
09/08/2020

Andrew Hirsch Named Chief Executive Officer of C4 Therapeutics

READ MORE
C4-logo-400
07/15/2020

C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer

READ MORE
C4-logo-400
06/16/2020

C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept and to Advance Proprietary Platform

READ MORE
C4-logo-wht
06/16/2020

C4 Therapeutics raises $170 million to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept

READ MORE
Logo-Geneoscopy-400
01/13/2020

Geneoscopy’s Preventive Screening Test for Colorectal Cancer and Precancerous Adenomas Earns FDA Breakthrough Device Designation

READ MORE
Logo-Geneoscopy-400
10/02/2019

Geneoscopy Raises $6.9 million to Advance Preventive Screening Test for Colorectal Cancer

READ MORE

PORTFOLIO HIGHLIGHTS

WUGEN Logo
White C4 Therapeutics logo
Geneoscopy logo
NextRNA Logo
CareVet Logo
microbial-logo-header300